An overview of the patient and normal healthy volunteer cohorts, population codes, patient numbers, and sampling visits for samples collected during the project and located within the TransBioLine Biosample Repository can be seen in the table below.
The secondary use of biosamples and sharing with third parties is dependent on the underlying consent (at patient level).
Please send inquiries on sample availability to sophia.samodelov@usz.ch and Alexandra.stege@charite.de.
| Cohort | Pop code | Patients [n] | Visits [n] |
|---|---|---|---|
| DIKI – drug-induced kidney injury (WP1) Matrices collected: double spun plasma (POP 10, 11,12,13), serum, urine |
|||
| Pregnant controls – at risk for pre-eclampsia, without pre-eclampsia | 10 | 21 | 9 |
| Anti-VEGF patients, with or without proteinuria§ | 11,12,13 | 21 | 5 |
| Anti-VEGF control (oncology patients on alternative therapy) § | 14 | 24 | 5 |
| DILI – drug-induced liver injury (WP2) Matrices collected: plasma, double spun plasma (miRNAs), serum (not for POP 23) |
|||
| DILI and non-DILI controls | 20 | 375 | 2 |
| MASLD/AFLD | 21 | 203 | 1 |
| Rheumatoid arthritis or psoriasis patients (with or without methotrexate therapy) | 22 | 81 | 1 |
| Non-DILI elevated transaminases (NOV) | 23 | 35 | 4 |
| DIPI- drug-induced pancreatic injury (WP3) Matrices collected: plasma, double spun plasma (miRNAs), serum, urine, packed cells |
|||
| MAP-I Drug-associated acute pancreatitis | 30 | 40 | 3 |
| MAP-I Other cause acute pancreatitis | 31 | 40 | 3 |
| MAP-I Chronic pancreatitis | 32 | 24 | 1 |
| MAP-I Pancreatic cancer | 33 | 14 | 1 |
| MAP-I Diabetes Mellitus | 34 | 25 | 1 |
| MAP-I Healthy volunteers | 77 | 57 | 1 |
| DIVI- drug induced vascular injury (WP4) Matrices collected: plasma, double spun plasma (miRNAs), serum |
|||
| Mechanic injury (angioplasty) | 40 | 4 | 2 |
| Large vessel injury (Takayasu arteritis/TAK) | 41 | 9 | 2 |
| Large vessel injury (Giant cell arteritis/GCA) | 42 | 33 | 2 |
| Medium/small vessel injury (ANCA-associated) | 43 | 18 | 2 |
| DINI- drug induced nervous system injury (WP5) Matrices collected: serum, CSF (for 50, 51, and 77) |
|||
| ChemoBrain – Chemotherapy-induced neurotoxicity | 50 | 49º | 10 |
| Multiple Sclerosis | 51 | 48 | 3 |
| Traumatic brain injury (TBI) | 52 | 140º | 1 |
| CAR-T cell therapy or intrathecal chemotherapy | 53 | 30 | 4 |
| Healthy volunteers | 77 | 10 | 3 |
| NHV – normal healthy volunteers Matrices collected: indicated below |
|||
| Pfizer WP5: serum | 77 | 273 | 1 |
| Pfizer WP1,2,4,6: plasma, double-spun plasma (miRNAs), serum, urine | 77 | 126 | 3 |
| Lilly: plasma, double-spun plasma (miRNAs), urine | 77 | 60 | 3* |
| Roche: plasma, double-spun plasma (miRNAs) | 77 | 50 | 3* |
| JnJ: double spun plasma (miRNAs) | 66 | 96 | 1 |
| JnJ: serum | 77 | 23 | 1 |
§ the collective contains samples that only allow a limited number of analyses due to processing irregularities.
°stored elsewhere
*not fasted (enrollment), fasted, and post-prandial
Abbreviations: Pop code – population code, DILI – drug-induced liver injury, MASLD – metabolic dysfunction-associated liver disease, AFLD – alcoholic fatty liver disease, MAP-I – study acronym, ANCA – antineutrophil cytoplasmic antibodies.